Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
UNIVERSITE D'AIX-MARSEILLE is currently managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. This level of activity suggests a focused research output with multiple active paths toward patent allowance. The institution is likely prioritizing these specific filings to protect its academic or commercial interests in the biotech sector through these 2 pending office actions.
The prosecution is split between 2 distinct examiners and 2 distinct art units. This complete separation means that each pending action is being evaluated in a unique technical context by a different individual. Such a structure prevents a single examiner's perspective from dominating the institution's entire patent outlook, providing a measure of procedural diversity across 2 distinct art units. This distribution suggests the institution's innovations span multiple technical subclasses.
ROONEY, NORA MAUREEN is the busiest examiner for the portfolio, with 1 busiest examiner pending action under their review. Since the total number of pending actions is 2, this examiner's influence is limited to half of the active workload. This distribution requires the institution to maintain distinct advocacy strategies tailored to the specific preferences of two different examiners. The presence of 1 busiest examiner pending action for the lead examiner indicates a balanced distribution of work.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MIDDLETON, DANAYA L | 1 | 49.5% | +48.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17040109 | METHODS FOR MODULATING INNATE LYMPHOID CELL ACTIVITY, ANTIBODY DRUG CONJUGATES AND USES IN THERAPY | MIDDLETON, DANAYA L | 10d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17040109 | METHODS FOR MODULATING INNATE LYMPHOID CELL ACTIVITY, ANTIBODY DRUG CONJUGATES AND USES IN THERAPY | MIDDLETON, DANAYA L | 10d overdue |
| Art Unit | Apps |
|---|---|
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17040109 | METHODS FOR MODULATING INNATE LYMPHOID CELL ACTIVITY, ANTIBODY DRUG CONJUGATES AND USES IN THERAPY | MIDDLETON, DANAYA L | 1674 | §103§112 | Non-Final OA | 10d overdue | Pending | Sep 22, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUNIVERSITE D'AIX-MARSEILLE has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Danaya L Middleton has the most, with 1 of UNIVERSITE D'AIX-MARSEILLE's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
